Placebo-controlled evidence across 9013 patients showed a lower composite risk (HR 0.85) driven by reduced worsening HF ...

Scott Shannon, MD, discusses psychedelic therapies, federal policy shifts, and the barriers slowing mental health innovation.

Meanwhile, ctDNA, a subset of cell-free DNA shed by tumors into the bloodstream, has emerged as a promising non-invasive risk stratification tool. Detection of ctDNA following curative-intent surgery, ...

Young adults with early-onset colorectal cancer (EOCRC), particularly men and non-Hispanic Black and American Indian/Alaskan ...

Santa Clara County Public Health issued a South Bay health alert after 18 Legionella cases were linked to Kaiser Santa Clara, ...

Anton M. Kolomeyer, MD, PhD, a retina specialist at NJRetina, spoke with The American Journal of Managed Care ® about ...

In part 2, Deborah Doroshow, MD, PhD, discusses early clinical trial access, emerging lung cancer therapies, and barriers to ...

A formal FDA call for repurposing nominations prioritizes areas where unmet need is high and manufacturer incentives to pursue supplemental approvals are limited. Submissions may be grounded in ...

The null finding held up even when researchers sliced the data by geography, income, insurance type, and social vulnerability ...

Label expansion enables serotype-agnostic use of FcRn blockade in adult gMG, positioning both IV Vyvgart and SC Vyvgart Hytrulo as first approved options regardless of antibody status. ADAPT SERON ...

Trump aims to accelerate the research, regulation, and integration of psychedelic-assisted therapies into US health care, ...

A cruise-ship cluster with three deaths triggered international public health response, including environmental assessments, isolation measures, and medical evacuation of symptomatic passengers for ...